Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics
AssigneeInternational - Drug - Development - Biotech
InventorsClaudine Vermot-Desroches, Chanthy Kong-Flohr, Marc Godinat, Bruno Cavallini
Life of this patent
Estimating the term…
Abstract
The invention relates to novel combination therapies involving anti-CD19 antibodies for the treatment of cancer B cells expressing CD19. One preferred method is where the anti-CD19 proapoptotic MAb or a Fc optimized proapototic humanized MAb. In the methods of the present invention some anti-CD20 agents such as Rituxan®, or chemodrugs such as vincristine may be used in combitherapy. The methods of the present invention reduce the levels of B CD19 positive, more particularly in all diffuse large B cells lymphoma (DLBCL) subtypes and in Follicular lymphomas (FL).
Claims9
Humanized monoclonal anti-CD19 antibody, having the following CDRs:
- Sequence
- SEQ
- SEQ
- SEQ
- (Common
- ID
- Sequence
- ID
- Sequence
- ID
- numbering
- NO:
- IMGT
- NO:
- Kabat
- NO:
- system)
- VH IDD001
- CDR1
- 5
- GYAFSSYW
- 11
- SYWVN
- 16
- SSYW
- CDR2
- 6
- IYPGDGDT
- 12
- QIYPGDGDT
- 6
- IYPGDGDT
- NYNGKFKG
- CDR3
- 7
- ARSITTVV
- 13
- SITTVVGCA
- 13
- SITTVVGC
- GCAMDY
- MDY
- AMDY
- VL IDD001
- CDR1
- 41
- QSINNW
- 42
- KASQSINNW
- 41
- QSINNW
- LA
- CDR2
- 43
- GAS
- 44
- GASTLET
- 43
- GAS
- CDR3
- 10
- QQSWNTP
- 10
- QQSWNTPW
- 10
- QQSWNT
- WT
- T
- PWT.
Dependencies are inferred from the claim text.